MI-LINEAGE-LOGISTICS
28.10.2021 15:02:07 CEST | Business Wire | Press release
Lineage Logistics, LLC (“Lineage” or the “Company”), the world’s largest and most innovative temperature-controlled industrial REIT and logistics solutions provider, today announced the launch of the Lineage Foundation for Good (the “Foundation”), an independent nonprofit aimed at reducing food waste and fighting food insecurity to support the global communities where over 21,000 of Lineage’s team members live and work.
According to the Food and Agriculture Organization of the United Nations (FAO) and the UN Environment Programme (UNEP), an estimated one-third of all food produced globally for human consumption is wasted. Of that number, over 40% is attributed to wasted food in the U.S., which equates to roughly 1.3 billion tons of food and 7% of greenhouse gas emissions. By comparison, 30% of temperature-controlled food products in the U.S. and nearly 10% globally travel through Lineage’s warehouse network. As a result, the Company’s unique visibility into its customers’ inventories and the greater food supply chain allows Lineage to proactively identify and facilitate donations of product that might have otherwise gone to waste.
“Given our role in the food supply chain, Lineage recognized that we are in a unique position to leverage our global network of resources to make an impact in the communities where we live and work,” said Greg Lehmkuhl, Lineage’s President and CEO. “The Lineage Foundation for Good creates a real-time link to redirect for donation quality products from food producers and manufacturers that might otherwise go to waste. The Foundation will further fuel our purpose to help feed the world and reimagine the global food ecosystem by limiting its environmental impact through food waste.”
The Foundation, which was created by a $3 million gift from Lineage, will leverage the Company’s access, influence, experience, and expertise in areas like logistics, automated warehousing, cold storage, data science, and distribution to address and improve the global food supply chain’s carbon imprint, reimagine industry processes that have historically led to food waste, and quickly redirect food to be distributed to communities around the world. Darcee Scavone, Lineage’s Vice President of Talent, Culture and Community Engagement, will oversee coordination between the Company and the Foundation and serve as the point of contact internally.
“Heightened by the COVID-19 pandemic, food insecurity is a pressing issue that millions around the globe are facing. Now, more than ever, people need access to quality food, and we are proud to be part of the solution to bring it to them,” said Darcee Scavone. “We have long partnered with the Global FoodBanking Network and Feeding America® and are building on this commitment by putting a vehicle – the connective tissue – in place to facilitate both food and financial donations, as well as promote volunteerism, globally.”
In addition to supporting Lineage’s philanthropic efforts, the Foundation will also support initiatives and organizations that align to its mission and work towards innovative and sustainable solutions to help reduce waste and fight food insecurity.
“Efforts to alleviate hunger and reduce food loss and waste are interlinked and vitally important,” said Lisa Moon, CEO and president of The Global FoodBanking Network. “Lineage Logistics has already demonstrated its commitment to addressing these issues by partnering with food banks globally, and the creation of the Lineage Foundation for Good further underscores this commitment. GFN is looking forward to the increased impact that will be possible as we work together to support community-driven solutions to address food insecurity worldwide.”
“America has more than enough food to feed everyone. But each year, billions of pounds of perfectly good food go to waste,” said Casey Marsh, Chief Development Officer at Feeding America. “Feeding America is the country's largest food rescue organization, and we applaud Lineage Logistics in their efforts to assure food isn’t wasted and gets to food banks serving our neighbors.”
In addition to partnering with the Global FoodBanking Network and Feeding America, the Foundation also works with similarly minded regional and local organizations.
The Foundation operates as a public charity under its own leadership and organizational structure, including a Board of Directors that will oversee all activities and business affairs. The Foundation also plans to accept multi-year annual contributions from Lineage, as well as gifts and direct donations from other individuals and organizations whose work is aligned with its mission to fight food insecurity, reduce food waste, and feed the world.
For more information and updates, please visit Lineage Foundation for Good .
About Lineage Foundation for Good
The Lineage Foundation for Good (the “Foundation”) is the independent philanthropic arm of Lineage Logistics, LLC (“Lineage”). The Foundation leverages the unique access, influence, experience, and expertise of Lineage, one of the world’s largest temperature-controlled logistics solutions providers, and its customers and partners to reduce food waste and fight food insecurity – a need that was accelerated by the practical challenges of getting quality food to those in need during the COVID-19 pandemic. Central to the Foundation’s mission is to develop a dynamic, real-time, and global link between those who commercially produce our food and the individuals, families, and communities who need it most. The Foundation creates a system in which food products, including those that might have otherwise gone to waste, can be quickly and easily steered to food pantries and other non-profits combatting food insecurity around the world. The Foundation supports various philanthropic initiatives that have an impact in the communities in which we live and work, and is proud to partner with Feeding America, the Global FoodBanking Network, and other organizations to expand its reach, maximize its impact, and help feed the world.
About Lineage Logistics
Lineage Logistics is the world’s largest temperature-controlled industrial REIT and logistics solutions provider. It has a global network of over 400 strategically located facilities totaling over 2 billion cubic feet of capacity which spans 15 countries across North America, Europe and Asia-Pacific. Lineage’s industry-leading expertise in end-to-end logistical solutions, its unrivaled real estate network, and development and deployment of innovative technology help increase distribution efficiency, advance sustainability, minimize supply chain waste, and most importantly, as a Visionary Partner of Feeding America, help feed the world. In recognition of the company’s leading innovations and sustainability initiatives, Lineage was listed as No. 17 in the 2021 CNBC Disruptor 50 list, the No 1. Data Science company, and 23rd overall, on Fast Company’s 2019 list of The World’s Most Innovative Companies, in addition to being included on Fortune’s Change The World list in 2020.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211028005216/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
